We canāt show the full text here under this license. Use the link below to read it at the source.
Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease
Combination therapy as a new standard treatment for chronic kidney disease with and without diabetes
AI simplified
Abstract
Combination therapy is emerging as a new standard for (CKD) treatment.
- Multiple therapies, including SGLT2 inhibitors and mineralocorticoid receptor antagonists, may reduce the risk of kidney failure and heart problems in CKD patients.
- Clinical trials suggest that each class of therapy provides independent and additive benefits, even when used alongside other medications.
- SGLT2 inhibitors may improve safety by reducing hyperkalaemia and fluid retention, potentially enhancing the tolerability of other treatments.
- Recent approvals and ongoing evaluations for therapies in conditions like IgA nephropathy indicate a growing range of options for CKD management.
- A multi-medicine approach could optimize patient-centered care and mitigate long-term risks associated with kidney failure.
AI simplified
Key numbers
35%
35% Relative Risk Reduction
Relative risk reduction in major cardiovascular events with combination therapy compared to alone.
55%
55% Reduction in Hospitalization
Reduction in hospitalization for heart failure associated with combination therapy in patients.
58%
58% Reduction in Progression
Reduction in progression with combination therapy compared to alone.